FDA Rejects Ivonescimab Filing Over Evidence Portability

Company Summit Therapeutics (Akeso licensor) Event Type FDA complete response letter (previously missed 15 Nov disclosure) Modality PD-1×VEGF bispecific antibody Asset Ivonescimab (AK112, SMT112) Target PD-1; VEGF Disease Area EGFR-mutant non-small-cell lung cancer after EGFR TKI Summary FDA issued a complete response letter for Summit’s…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *